Aberdeen Group plc lifted its position in Docusign Inc. (NASDAQ:DOCU - Free Report) by 130.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 108,969 shares of the company's stock after acquiring an additional 61,598 shares during the period. Aberdeen Group plc owned approximately 0.05% of Docusign worth $8,870,000 at the end of the most recent quarter.
Other hedge funds have also modified their holdings of the company. New Age Alpha Advisors LLC raised its position in shares of Docusign by 738.2% in the 1st quarter. New Age Alpha Advisors LLC now owns 41,187 shares of the company's stock valued at $3,353,000 after acquiring an additional 36,273 shares during the period. Pinpoint Asset Management Ltd raised its position in shares of Docusign by 54.3% in the 1st quarter. Pinpoint Asset Management Ltd now owns 56,985 shares of the company's stock valued at $4,639,000 after acquiring an additional 20,043 shares during the period. Concurrent Investment Advisors LLC acquired a new stake in shares of Docusign in the 1st quarter valued at approximately $618,000. Gilman Hill Asset Management LLC lifted its holdings in shares of Docusign by 4.9% during the 1st quarter. Gilman Hill Asset Management LLC now owns 84,326 shares of the company's stock valued at $6,864,000 after purchasing an additional 3,904 shares in the last quarter. Finally, Blair William & Co. IL lifted its holdings in shares of Docusign by 1.7% during the 1st quarter. Blair William & Co. IL now owns 387,542 shares of the company's stock valued at $31,546,000 after purchasing an additional 6,460 shares in the last quarter. 77.64% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Several research firms have recently weighed in on DOCU. Wells Fargo & Company upgraded Docusign from an "underweight" rating to an "equal weight" rating and lifted their price objective for the company from $67.00 to $80.00 in a report on Friday, June 13th. Morgan Stanley cut their price objective on Docusign from $92.00 to $86.00 and set an "equal weight" rating on the stock in a report on Friday, June 6th. Robert W. Baird cut their price objective on Docusign from $93.00 to $85.00 and set a "neutral" rating on the stock in a report on Friday, June 6th. JPMorgan Chase & Co. cut their price objective on Docusign from $81.00 to $77.00 and set a "neutral" rating on the stock in a report on Friday, June 6th. Finally, Wall Street Zen cut Docusign from a "buy" rating to a "hold" rating in a report on Saturday, August 2nd. Four equities research analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the stock. According to data from MarketBeat.com, Docusign presently has a consensus rating of "Hold" and an average price target of $89.77.
View Our Latest Stock Report on Docusign
Docusign Stock Performance
NASDAQ DOCU traded up $4.07 during trading on Friday, hitting $74.81. The stock had a trading volume of 2,692,758 shares, compared to its average volume of 2,172,880. The company has a market capitalization of $15.12 billion, a PE ratio of 14.14, a P/E/G ratio of 27.92 and a beta of 1.01. The company's 50-day moving average price is $75.47 and its two-hundred day moving average price is $80.27. Docusign Inc. has a 12 month low of $54.31 and a 12 month high of $107.86.
Docusign (NASDAQ:DOCU - Get Free Report) last released its earnings results on Thursday, June 5th. The company reported $0.90 EPS for the quarter, beating the consensus estimate of $0.81 by $0.09. The firm had revenue of $763.65 million for the quarter, compared to analysts' expectations of $748.79 million. Docusign had a return on equity of 14.27% and a net margin of 36.50%.The business's quarterly revenue was up 7.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.82 EPS. Docusign has set its FY 2026 guidance at EPS. Q2 2026 guidance at EPS. As a group, equities analysts anticipate that Docusign Inc. will post 1.17 earnings per share for the current fiscal year.
Docusign announced that its Board of Directors has approved a share repurchase plan on Thursday, June 5th that permits the company to repurchase $1.00 billion in shares. This repurchase authorization permits the company to buy up to 6.6% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company's board of directors believes its stock is undervalued.
Insider Buying and Selling
In related news, CFO Blake Jeffrey Grayson sold 15,143 shares of the business's stock in a transaction on Wednesday, June 18th. The shares were sold at an average price of $74.80, for a total transaction of $1,132,696.40. Following the transaction, the chief financial officer directly owned 110,723 shares in the company, valued at approximately $8,282,080.40. The trade was a 12.03% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Allan C. Thygesen sold 40,000 shares of the business's stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $77.51, for a total transaction of $3,100,400.00. Following the transaction, the chief executive officer owned 143,983 shares in the company, valued at approximately $11,160,122.33. The trade was a 21.74% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 78,552 shares of company stock worth $5,983,631 over the last 90 days. Company insiders own 1.01% of the company's stock.
Docusign Company Profile
(
Free Report)
DocuSign, Inc provides electronic signature solution in the United States and internationally. The company provides e-signature solution that enables sending and signing of agreements on various devices; Contract Lifecycle Management (CLM), which automates workflows across the entire agreement process; Document Generation streamlines the process of generating new, custom agreements; and Gen for Salesforce, which allows sales representatives to automatically generate agreements with a few clicks from within Salesforce.
Read More

Before you consider Docusign, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Docusign wasn't on the list.
While Docusign currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.